Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

However, Lilly’s GLP-1 products have shown better results in clinical studies. In an earlier head-to-head study, LLY’s Zepbound has shown superior weight loss than NVO’s Wegovy.

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Lilly has shared few details about eloralintide before now, because it’s still in the early stages of testing. It’s part of a class of drugs that mimic the hormone amylin, which slows ...